🇺🇸 FDA
Patent

US 10711007

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

granted A61PA61P35/00

Quick answer

US patent 10711007 (Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)) held by Prelude Therapeutics, Incorporated expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Prelude Therapeutics, Incorporated
Grant date
Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P35/00